Patents by Inventor Christian Steidl

Christian Steidl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPATIAL METRIC MEASUREMENT METHODS FOR MULTIPLEX IMAGING AND USES IN TUMOR SAMPLE ANALYSIS
    Publication number: 20240402183
    Abstract: Spatial analysis methods based on nearest neighbor analysis are provided of specific regions of tissue to describe cancer states and develop biomarkers to predict outcomes. In various embodiments, the spatial analysis methods involve an interaction radius to computationally isolate local interactions and prevent the data from being influenced by cells that are very far away. Thereby, spatial analysis of cancer tissue can be quickly and consistently performed in an automated fashion to focus on tumor-immune cell biology, which occurs at a localized level.
    Type: Application
    Filed: May 31, 2024
    Publication date: December 5, 2024
    Applicants: CEDARS-SINAI MEDICAL CENTER, BC CANCER, part of the Provincial Health Services Authority
    Inventors: Alexander Xu, Akil Merchant, Anthony Colombo, Tomohiro Aoki, Aixiang Jiang, Christian Steidl
  • Method for determining lymphoma type and providing treatment
    Patent number: 11646099
    Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: May 9, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency, Mayo Foundation for Medical Education and Research, Julius-Maximilians-University of Würzburg, Boatd of Regents of the University of Nebraska, Oslo University Hospital HF, Hospital Clinic de Barcelona, Universitat de Barceloa, Institut D'Investigacions Biomédiques Pi I Sunyer (IDIBAPS), Robert Bosch Gesellschaft feuer medizinische Forshung mbH, Oregon Health & Science University, City of Hope, The Cleveland Clinic Foundation
    Inventors: Louis M. Staudt, Christian Steidl, Anja Mottok, George W. Wright, David William Scott, Lisa M. Rimsza, Andreas Rosenwald, Randy Gascoyne, Timothy Greiner, Dennis Weisenburger, Erlend B. Smeland, Jan Delabie, Elias Campo Guerri, German Ott, Rita Braziel, Elaine S. Jaffe, Kai Fu, Wing C. Chan, Joo Song, James R. Cook
  • Identification and use of new tumor-promoting gene in hematological malignancies
    Patent number: 10941209
    Abstract: Methods are provided for diagnosing and treating a blood cancer or a myelodysplastic syndrome in a subject. Associated compositions and kits therefor are also provided.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: March 9, 2021
    Assignees: Albert Einstein College of Medicine, British Columbia Cancer Agency Branch
    Inventors: Ulrich Steidl, Christian Steidl, Ujunwa Cynthia Okoye-Okafor
  • METHOD FOR DETERMINING LYMPHOMA TYPE
    Publication number: 20200105364
    Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 2, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, British Columbia Cancer Agency Branch, Mayo Foundation for Medical Education and Research, Julius-Maximilians-University of Würzburg, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Hospital Clinic de Barcelona, Universitat de Barcelona, Institut D? Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Robert Bosch Gesellschaft fuer medizinische Forschung mbH, Oregon Health & Science University, City of Hope, The Cleveland Clinic Foundation
    Inventors: Louis M. Staudt, Christian Steidl, Anja Mottok, George W. Wright, David William Scott, Lisa M. Rimsza, Andreas Rosenwald, Randy Gascoyne, Timothy Greiner, Dennis Weisenburger, Erlend B. Smeland, Jan Delabie, Elias Campo Guerri, German Ott, Rita Braziel, Elaine S. Jaffe, Kai Fu, Wing C. Chan, Joo Song, James R. Cook
  • IDENTIFICATION AND USE OF NEW TUMOR-PROMOTING GENE IN HEMATOLOGICAL MALIGNANCIES
    Publication number: 20180371105
    Abstract: Methods are provided for diagnosing and treating a blood cancer or a myelodysplastic syndrome in a subject. Associated compositions and kits therefor are also provided.
    Type: Application
    Filed: July 20, 2018
    Publication date: December 27, 2018
    Inventors: Ulrich Steidl, Christian Steidl, Ujunwa Cynthia Okoye-Okafor
  • IDENTIFICATION AND USE OF NEW TUMOR-PROMOTING GENE IN HEMATOLOGICAL MALIGNANCIES
    Publication number: 20150329643
    Abstract: Methods are provided for diagnosing and treating a blood cancer or a myelodysplastic syndrome in a subject. Associated compositions and kits therefor are also provided.
    Type: Application
    Filed: November 15, 2013
    Publication date: November 19, 2015
    Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
    Inventors: Ulrich Steidl, Christian Steidl, Cynthia Ujunwa Okoye-Okafor
  • PREDICTING PROGNOSIS IN CLASSIC HODGKIN LYMPHOMA
    Publication number: 20140303034
    Abstract: Predictor genes and methods for determining prognosis in classic Hodgkin's lymphoma (cHL) are described herein. Expression levels of predictor genes ALDH1A1, APOL6, B2M, CD300A, CD68, CXCL11, GLUL, HLA-A, HLA-C, IFNG, IL15RA, IRF1, LMO2, LYZ, PRF1, RAPGEF2, RNF144B, STAT1, TNFSF10, WDR83, CCL17, COL6A1, and PDGFRA are used to derive a score within a prognostic model. Measurement of expression levels may involve counting RNA molecules using digital profiling, such as the NanoString™ platform. The score is compared to a threshold indicative of outcome. Associated kits, commercial packages, panels of biomarkers, and uses are also provided.
    Type: Application
    Filed: December 7, 2012
    Publication date: October 9, 2014
    Inventors: Randy Gascoyne, Christian Steidl, David Scott